Clinical Trials

103 enrolled

Carcinoma, Transitional Cell

NCT03661320 2026-04-15

A Study to Compare Chemotherapy Alone Versus Chemotherapy Plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Therapy After Surgery With Nivolumab or Nivolumab and BMS-986205 in Participants With Muscle Invasive Bladder Cancer

855 enrolled

Urinary Bladder Neoplasms

NCT03967977 2026-04-15

Study of Tislelizumab in Combination With Chemotherapy Compared to Chemotherapy Alone for Participants With Urothelial Carcinoma

Phase 3 Recruiting

420 enrolled

Phase 4 Active not recruiting

Carcinoma, Transitional Cell

NCT04597125 2026-04-15

RADIANT: A Study of Radium-223 Dichloride (Xofigo) vs Enzalutamide or Abiraterone (ARPIs, Androgen Receptor Pathway Inhibitors) in Patients With Prostate Cancer That Has Spread to the Bones (mCRPC, Metastatic Castration-Resistant Prostate Cancer)

654 enrolled

Phase NA Active not recruiting

Metastatic Castrate Resistant Prostate Cancer (mCRPC)

NCT04905069 2026-04-15

SABRE

500 enrolled

GenitourinaryGynecologicThoracic

Neoplasms, Prostatic Neoplasms

NCT05397093 2026-04-15

ITIL-306 in Advanced Solid Tumors

Phase 1 Terminated

1 enrolled

Carcinoma, Ovarian Epithelial, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Fallopian Tube Neoplasms

NCT05483868 2026-04-15

A Phase 1, Open-label Trial of Belzupacap Sarotalocan (AU-011) in Bladder Cancer

55 enrolled

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

NCT05581004 2026-04-15

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors

DermatologicGastrointestinalGenitourinaryGynecologicHead & Neck

450 enrolled

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Melanoma, Stomach Neoplasms, Colorectal Neoplasms

NCT06136650 2026-04-15

MK-5684-004

Phase 3 Recruiting

1,314 enrolled

Phase 2/3 Active not recruiting

Prostatic Neoplasms

NCT06225596 2026-04-15

Study BT8009-230 in Participants With Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2)

956 enrolled

Urinary Bladder Neoplasms

NCT06511141 2026-04-15

Sacral Neuromodulation for Male Overactive Bladder (MOAB)

Phase NA Recruiting

150 enrolled

Prostatic Hyperplasia, Prostatic Neoplasms, Urinary Bladder, Overactive

NCT07106762 2026-04-15

Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy

Phase 2/3 Recruiting

470 enrolled

Phase 1 Active not recruiting

Urinary Bladder Neoplasms

NCT07236112 2026-04-15

Study of TRDC002 in the Diagnosis of Patients With PSMA-positive Prostate Cancer

6 enrolled

Prostatic Neoplasms

NCT07475806 2026-04-15

A Study to Find Out if Enfortumab Vedotin Given With Pembrolizumab Helps People With Muscle-invasive Bladder Cancer Keep Their Bladder

Phase 2 Recruiting

240 enrolled

Phase 1 Not yet recruiting

Muscle-invasive Bladder Cancer

NCT07518043 2026-04-15

A Study of HLX18 vs. OPDIVO® in Multiple Resected Solid Tumors

174 enrolled

DermatologicGenitourinary

Carcinoma, Transitional Cell, Melanoma

NCT03091192 2026-04-14

Savolitinib vs. Sunitinib in MET-driven PRCC.

60 enrolled 15 charts

Carcinoma, Carcinoma, Renal Cell, Kidney Diseases, Kidney Neoplasms, Neoplasms by Site, Urologic Neoplasms

NCT03528694 2026-04-14

POTOMAC

1,018 enrolled

Non-Muscle Invasive Bladder Neoplasms

NCT04960709 2026-04-14

VOLGA

712 enrolled

Urinary Bladder Neoplasms

NCT05847166 2026-04-14

A Phase 2/3,PSMA-T4, Prostate Cancer

Phase NA Recruiting

80 enrolled

Prostatic Neoplasms

NCT06026410 2026-04-14

FIT-001

GastrointestinalGenitourinaryThoracic

300 enrolled

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Kidney Neoplasms, Colorectal Neoplasms

NCT06122584 2026-04-14

Diagnostic Performance of [18F]PSMA-1007 PET/CT Imaging in Patients With Newly-Diagnosed Prostate Cancer

Phase 3 Recruiting

380 enrolled

Prostatic Neoplasms

NCT07195916 2026-04-14

A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies